I solated submental liposis presents an enticing opportunity in facial and plastic surgery because a reduction can alter facial contours and provide a significant improvement to the frontal and profile views. An aesthetically pleasing jawline often relies on reduction of submental fat. Historically, the problem has been addressed with liposuction in a variety of forms. Ilouz 1 first described the use of a 5-mm cannula and a lateral approach to fat elimination of the body in 1979. Hetter 2 later described the use of a smaller cannula through the submental approach and the addition of infralobular incisions, which improved the contours of the postoperative result. 3 As the procedure has evolved, an emphasis on improving safety and using adjunctive treatments to provide skin tightening have augmented the results of wellperformed submental liposuction. Although the procedure is often performed in conjunction with a face-lift to address the aging face, it is also performed alone to improve hereditary isolated submental fat deposition that can create the impression of an overweight face. As evident in other aesthetic procedures, treatment of submental liposis has evolved from the operating room toward a less invasive approach. In April 2015, the US Food and Drug Administration approved the use of a formulation of synthetic (nonanimal and nonhuman) deoxycholic acid (Kybella; Allergan Plc) for the treatment of moderate to severe submental fat. 4 To date, multiple North American and European phase 3, double-blinded clinical trials have been performed. [5] [6] [7] [8] [9] These trials have manifested an excellent safety profile and significant clinical efficacy of sodium deoxycholate acid injection, known as ATX-101 in the clinical studies. The following review provides a pooled analysis of the results of these trials, specifically describing the efficacy of the phase 3 clinical trial data compared with submental liposuction and an analysis of current use of the product among facial plastic surgeons.
Methods
We began by performing an analysis of the 2 European and 2 North American phase 3 trials. [5] [6] [7] [8] [9] Available data from the studies were pooled and analyzed. In addition, Allergan Plc provided unpublished data from each of the cohorts. We used 2-sample paired t tests to determine whether a statistical difference existed in the percentage of patients who experienced pain, numbness, bruising, and edema between the placebo and pooled ATX-101 treatment groups. An online survey was emailed to all 2700 members of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). Respondents were asked about their current management of submental liposis, including techniques and costs, and queried regarding their experience with deoxycholic acid. Demographic data were also collected. Results were organized in Google Forms and analyzed in Excel software (version 2010; Microsoft Corp). P < .05 indicated significance. Deoxycholic acid is fiscally efficacious for patients with mild to moderate submental liposis who will require 20 to 30 mg of drug per treatment for 3 treatment sessions for a total of 60 to 90 mg.
Results
Meaning For patients requiring large amounts of deoxycholic acid, surgical liposuctions might be a more economical treatment modality. higher scores indicating a visually assessed very large amount of chin fat) performed by the patient and a blinded physician.
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At 12 weeks after the final treatment, the proportion of treatment responders (>1-point improvement in the 5-point clinician-reported Submental Fat Rating Scale) was found to be significantly greater for the ATX-101 groups (700 patients [70.2%]) than the placebo groups (248 patients [33.3%]; P = .003) in all studies ( Table 2 ). The mean (SD) number of treatment sessions that each participant underwent was 4.1 (0.5). In the total treatment arm, each patient received a mean (SD) dose of 186.0 (106.6) mg of ATX-101 (Table 3) . For the survey of the members of the AAFPRS, 102 responses were recorded, representing 4% of the AAFPRS membership. The cohort was balanced in regard to practice location, academic vs private practice, and years in practice ( Figure 1) . Overall, 65 AAFPRS respondents (63.7%) offered deoxycholic acid in their practice at the time of the survey. Three respondents previously offered it but then stopped using it secondary to cost and effectiveness. Of the 102 respondents, 88 (86.3%) stated that they performed the injections.
In regard to treatment protocol, 96 physicians who responded (94.1%) used a mean of 2 to 3 treatments, yielding a weighted mean (SD) number of 2.6 (0.6) injection sessions per patient. Average treatment sessions were scheduled from 3 to more than 6 weeks apart, with the largest number of respondents (49 [48.0%]) scheduling sessions 6 weeks apart. In regard to cost, a weighted mean (SD) cost to the patient was $691.04 ($168.68) per vial (20 mg/2 mL) of deoxycholic acid (Figure 2A) . Fifty-eight physicians (56.9%) stated that treatment cessation occurred at positive end points, including the patient being satisfied with treatment results or an absence of residual fat available for further treatment. Of interest, 28 respondents (27.4%) stated that the most common reason for treatment cessation was secondary to cost to the patient. The weighted mean (SD) total cost reported by surgeons to perform submental liposuction (including surgeon's fees, anesthesia, and facility fees) was $2976.56 ($1041.62) ( Figure 2B ).
Discussion
Although submental liposuction has long been the standard of care for addressing submental liposis, the advent of deoxycholic acid presents an intriguing option to patients. The current phase 3 studies mention submental liposuction as an alternative treatment; however, despite commenting on the efficacy of deoxycholic acid, none directly compares the 2 treatment modalities. With national television spotlights and extensive coverage from print media, [10] [11] [12] [13] deoxycholic acid has been portrayed as a novel wonder drug. Inherent in its quality as an injectable, deoxycholic acid portrays a shorter and easier recovery and less risk than surgical intervention to the average consumer. A similar perception is also that deoxycholic acid would cost less than a surgical procedure, such as submental liposuction. A detailed review comparing the recovery time and adverse effects of deoxycholic acid and submental liposuction requires a subjective approach. Although the ATX-101 clinical trials demonstrate an overall excellent safety profile, the common adverse effects of treatment are quantified but not qualified by severity. The data demonstrate that a significant number of patients experience pain, transient bruising, edema, and numbness. Given the subjective and variable nature of this experience and that of postliposuction recovery, the 2 are difficult to compare statistically. A literature review also identified minimal studies 14 outlining specific adverse events and complication rates of isolated submental liposuction. Further research, even retrospective reviews, are needed to help define complication rates and recovery from submental liposuction.
Although each patient experiences a variable recovery process, in our practice, we have witnessed nonquantifiable, comparable postprocedure outcomes in regard to swelling, bruising, and pain for both treatment modalities. This variability makes it difficult to compare them; however, several advantages of each modality are evident. Although deoxycholic acid almost always necessitates multiple treatments with a considerable duration between sessions, liposuction is almost always a single-modality treatment with an earlier final result. Other advantages of liposuction include the ability to perform a more lateral removal of fat because deoxycholic acid is only injected centrally to avoid injury to the marginal mandibular nerve, which was reported to be transient but as high as 4% in the phase 3 trials. [5] [6] [7] [8] Although liposuction can be performed with local infiltrative anesthesia, it often requires mild to moderate sedation for the wary patient. In addition, surgical incisions are required for liposuction, although we have found the incisions are well tolerated and have not required revision, even when visible, because incisions are limited to less than 1 cm and well hidden in the submental crease and earlobes. 15 Our study also identified several cost considerations that must be addressed when presenting patients with the options of deoxycholic acid injection vs submental liposuction. This issue was of particular importance to patients, as evident in Google Trends data, in which the top related search term associated with deoxycholic acid was cost. 16 An analysis of the estimated cost to treat the patients in the ATX-101 clinical trials 7 can be performed. The clinical trial population was injected with a mean of 186.0 mg of drug per patient. Based on the results of our survey, the average clinician charges $691.04 per 20-mg vial of deoxycholic acid, which would result in an average cost of $6426.35. In a comparative cost analysis, a weighted mean of the survey responses revealed an average total cost of liposuction of $2976.56. Our survey also found that common practice is different than the protocols established in the phase 3 trials. The weighted mean number of injections administered as reported in our survey was 2.6 treatment sessions compared with the 4.1 injections administered in the trials. Our survey did not address how many vials per treatment session were used for an average patient in clinical practice. This determination was based on the surface area of the safe injection zone bound by the anterior digastric muscles and the region above the hyoid bone. Although this area is variable in each patient, it is closely correlated with sex and body mass index. We believe that this area is the keystone variable in preoperative analysis that helps a clinician determine whether deoxycholic acid would be a costeffective treatment modality. Our data show that patients who only require 1.0 to 1.5 vials of deoxycholic acid (20-30 mg) per session can obtain cost efficacy. The mean cost of treatment, assuming 1 vial per session and 2.6 sessions, would be $1796.72.
Limitations
Our analysis is limited primarily by the lack of previous statistical studies on submental liposuction and the difficulty of standardizing a typical postoperative course to allow for headto-head comparison. Statistically, our survey did not provide us with a benchmark of accuracy equal to the data presented in the phase 3 trials. Ideally, a prospective study would incorporate the mean milligrams of drug injected per patient by each survey respondent. Previous literature on submental liposuction discussed the array of complications but did not quantify the resulting recovery period. 14, 15 In addition, our survey did not encompass the diverse specialty of clinicians who use the product. In a recent publication, Cohen and colleagues 17 identified that deoxycholic acid injection is not without recovery time or potential adverse effects and is not a 1-time treatment. They also recognized that undertreatment as a costsaving practice can be a potential area of concern for the future of the product. 17 To maximize patient satisfaction and reduce the number of patients in whom treatment cessation is based on cost limitation, our study helps guide clinicians in performing a cost-efficacy analysis for each potential patient.
Conclusions
Although patients are often averse to surgery, the clinicians are responsible (whether they provide both services) for discussing the risks and benefits of and alternatives to any proposed treatment. Although the US Food and Drug Administration indication for deoxycholic acid is moderate to severe submental fat reduction, we propose that deoxycholic acid is better suited for patients with mild to moderate submental liposis, and cost efficacy should be discussed after an estimation of how many vials will be needed in each session to be performed. If the cost of the drug to the patient decreases and the safety profile is further manifest, deoxycholic acid may become more popular. This study suggests that clinicians consider submental liposuction as a superior alternative in regard to cost and recovery for patients who will require more than 2 vials per treatment and more than 3 treatment sessions.
